Novartis AG is a global healthcare company that specializes in developing and manufacturing innovative pharmaceuticals and medical products. The company focuses on research-driven solutions in various therapeutic areas, including oncology, cardiology, immunology, and neuroscience, among others. Novartis is committed to improving patient health by providing high-quality medications and treatments, and it invests significantly in research and development to discover and deliver new therapies. In addition to its pharmaceutical division, Novartis also offers generics and biosimilars through its Sandoz division, making healthcare more accessible to patients worldwide.
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.
Janux Therapeutics reports updated clinical data for JANX007, highlighting significant efficacy, safety, and durability in advanced prostate cancer patients.
Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will receive $150 million upfront and eligible to receive up to approximately $2.3 billion in milestone payments plus royalties.
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.
Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments, and gene therapy.
Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a significant reduction in cancer recurrence in a Phase 3 trial. European Commission decision expected soon.
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales estimates of $700 million by 2031 for Empaveli and $2 billion for Syfovre by 2030.
